During the last session, Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares were 0.5 million, with the beta value of the company hitting 2.25. At the end of the trading day, the stock’s price was $1.52, reflecting an intraday gain of 1.33% or $0.02. The 52-week high for the ITRM share is $3.02, that puts it down -98.68 from that peak though still a striking 46.71% gain since the share price plummeted to a 52-week low of $0.81. The company’s market capitalization is $41.82M, and the average intraday trading volume over the past 10 days was 0.58 million shares, and the average trade volume was 3.08 million shares over the past three months.
Iterum Therapeutics Plc (ITRM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ITRM has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Iterum Therapeutics Plc (ITRM) registered a 1.33% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.33% in intraday trading to $1.52, hitting a weekly high. The stock’s 5-day price performance is -1.30%, and it has moved by -14.12% in 30 days. Based on these gigs, the overall price performance for the year is -20.00%. The short interest in Iterum Therapeutics Plc (NASDAQ:ITRM) is 2.53 million shares and it means that shorts have 0.46 day(s) to cover.
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Statistics show that Iterum Therapeutics Plc has outperformed its competitors in share price, compared to the industry in which it operates. Iterum Therapeutics Plc (ITRM) shares have gone up 17.83% during the last six months, with a year-to-date growth rate more than the industry average at 59.80% against 16.80.
Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 1.34M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.62%. While earnings are projected to return 65.98% in 2025.
ITRM Dividends
Iterum Therapeutics Plc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
Iterum Therapeutics Plc insiders own 1.81% of total outstanding shares while institutional holders control 8.99%, with the float percentage being 9.15%. BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC is the largest shareholder of the company, while 19.0 institutions own stock in it. As of 2024-06-30, the company held over 66.0 shares (or 0.0004% of all shares), a total value of $76.0 in shares.
Data provided on Nov 30, 2024 indicates that Fidelity NASDAQ Composite Index Fund owns about 12.37 shares. This amounts to just over 0.04 percent of the company’s overall shares, with a $18802.0 market value.
